GET DAILY SIGNALSSanara MedTech (SMTI): Refocusing on Its Surgical Solutions Portfolio
Key Takeaways
- Sanara MedTech Inc. is a medical technology company that develops, markets, and distributes surgical solutions for soft tissue repair and bone fusion, primarily used in operating rooms and surgical centers across the United States.
- The company trades on the Nasdaq under the ticker SMTI and is headquartered in Fort Worth, Texas.
- Its lead product, CellerateRX Surgical, is an activated collagen used to manage surgical and traumatic wounds, supported by a portfolio of antimicrobial and bone-graft technologies.
- In late 2025, Sanara discontinued its value-based wound care segment to refocus as a pure-play surgical products company.
- The business is built on a hospital-direct, hybrid sales model combining an internal field team with a large independent distributor network.
Getting to Know Sanara MedTech
Sanara MedTech Inc. (SMTI) supplies surgeons and hospitals with technologies designed to improve clinical outcomes while helping manage healthcare costs. I follow the stock because it operates in the specialized area of surgical wound care and bone healing, where clinical evidence, regulatory approvals, and hospital relationships can build lasting advantages. A good starting point is understanding what the company produces and how it reaches customers.
Company Background and Sales Approach
Sanara MedTech dates back to a Texas entity incorporated in 2001, formerly known as Wound Management Technologies, Inc. It is based in Fort Worth, Texas, and reports in the healthcare sector as a medical device and supplies business, with its fiscal year ending December 31. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The model centers on selling into surgical settings through two main categories: soft tissue repair and bone fusion. Soft tissue repair generates the larger share, led by CellerateRX Surgical, a hydrolyzed bovine Type I collagen for surgical, traumatic, and partial or full-thickness wounds plus first- and second-degree burns. Additional offerings include BIASURGE, a no-rinse antimicrobial surgical solution, and antimicrobial cleansers and gels under a licensing deal with Rochal.
In bone fusion, the lineup features BiFORM, an osteoconductive porous implant; ALLOCYTE Plus, a cellular bone matrix; FORTIFY Tissue Repair Graft; ACTIGEN; and TEXAGEN, a multi-layer amniotic membrane allograft. The pipeline includes OsStic, a synthetic bone adhesive that holds FDA Breakthrough Device designation for periarticular fractures.
Sales follow a hybrid approach that pairs an internal field team with a broad network of independent distributors. This setup supports national reach without proportional headcount growth. Management has indicated products are approved in more than 4,000 hospitals and surgery centers.
Strategic Shift and Financial Overview
A notable recent change was the decision to exit the value-based wound care segment, Tissue Health Plus. After that effort did not attract outside funding, operations ended in September 2025, leaving a single operating segment focused on surgical products.
Financially, Sanara posted record net revenue of about $103.1 million in 2025, a 19% increase from the prior year, alongside gross margins near 93%. Guidance for 2026 calls for revenue between $116 million and $121 million, pointing to continued double-digit growth. The company achieved GAAP net income from continuing operations in the first quarter of 2026 after earlier losses. Long-term debt remains on the balance sheet, and capital allocation now emphasizes reinvestment in the core surgical business.
What Draws Investors to SMTI
Several factors keep attention on Sanara MedTech. Its surgical products serve a recurring hospital-procedure market rather than discretionary spending, which can support steadier demand. High gross margins reflect the value of differentiated, evidence-backed items, and the hybrid distribution model provides a scalable route to wider adoption.
Competitive strength rests on clinical data and regulatory progress. Management points to published studies backing key products and contracts with major hospital purchasing organizations. OsStic stands out as a potential longer-term catalyst, described by management as a category creator in bone repair. The move to a pure-play surgical profile aims to sharpen focus and operating leverage.
Risks Worth Monitoring
Investors should weigh several risks. Sanara competes in a medical device space against larger, better-funded players with established hospital ties. Reliance on a limited set of core products, especially CellerateRX Surgical and BIASURGE, introduces concentration risk. Regulatory compliance with FDA standards is essential, and the OsStic launch hinges on further development, approvals, and execution. Long-term debt and occasional cash usage mean liquidity and covenant compliance matter. Exiting the value-based segment also leaves the company more exposed to surgical products dynamics.
AI Tools in My Research Process
When screening for ideas in medical technology and related sectors, I often turn to Tickeron’s AI-powered platforms to cross-check technical signals, fundamentals, and industry trends against my own analysis. One resource I find particularly useful is the AI Screener, which lets users apply customizable filters across thousands of stocks and ETFs to surface opportunities that match specific strategies. It has helped me efficiently compare names like SMTI with peers and refine my watchlist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
SMTI in downward trend: 10-day moving average moved below 50-day moving average on October 19, 2026
The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 57 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 59 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 186 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (36.493) is very high in comparison to the industry average of (4.964). P/E Ratio (-8.481) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement